Abstract:

Pterygium recurrence is one of the most common complications in pterygium surgery. And various medicines combined with surgery could further reduce the rates of recurrence. As traditional adjunctive therapies, anti-metabolic drugs have been applied to prevent the recurrence of pterygium for decades. However, mitomycin C has been not available  because of its shortage source, and 5-fluorouracil is less effective. Recently, some medicines such as anti-vascular endothelial growth factor agents, cyclosporine A and interferon, characterized by anti-proliferation and anti-angiogenesis, provide  new approaches to prevent the recurrence of pterygium. However, the high costs of above medicines and uncertain long-term effects are still huge problems. (Int Rev Ophthalmol,  2018,  42:   129-133)